Cancer Immunotherapies: Are They as Effective in the Elderly? (Q38679662)

5 September 2017

title

Cancer Immunotherapies: Are They as Effective in the Elderly? (English)

1 reference

5 September 2017

1 reference

Kate Poropatich

1

1 reference

5 September 2017

Joel Fontanarosa

2

1 reference

5 September 2017

Sandeep Samant

3

1 reference

5 September 2017

Jeffrey A Sosman

4

1 reference

5 September 2017

Bin Zhang

5

1 reference

5 September 2017

publication date

13 July 2017

1 reference

5 September 2017

1 reference

5 September 2017

volume

34

1 reference

5 September 2017

issue

8

1 reference

5 September 2017

page(s)

567-581

1 reference

FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

PS01.53: First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: Medical Oncology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Participation of patients 65 years of age or older in cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

The human thymus during aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Insights into thymic aging and regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Cancer vaccination: manipulation of immune responses at old age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Human T cell aging and the impact of persistent viral infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Direct measurement of T cell receptor affinity and sequence from naïve antiviral T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Considerations for successful cancer immunotherapy in aged hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Inflammation, ageing and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Targeting macrophages rescues age-related immune deficiencies in C57BL/6J geriatric mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Functional regulatory T cells accumulate in aged hosts and promote chronic infectious disease reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Optimization of immunotherapy in elderly cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

OX40-enhanced tumor rejection and effector T cell differentiation decreases with age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Aged mice develop protective antitumor immune responses with appropriate costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Are macrophages, myeloid derived suppressor cells and neutrophils mediators of local suppression in healthy and cancerous tissues in aging hosts?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Blood CD33( )HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

A Role for Immature Myeloid Cells in Immune Senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Approvals in 2016: the march of the checkpoint inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Immune checkpoint inhibitors in challenging populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Responses to immune checkpoint inhibitors in nonagenarians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Rituximab dose-escalation trial in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Follicular Lymphoma: The Management of Elderly Patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

A phase I trial of repeated tumour-infiltrating lymphocyte (TIL) infusion in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Phase I study of adoptive T-cell therapy using antigen-specific CD8 T cells for the treatment of patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Oncolytic viruses and their application to cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-863), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40266-017-0479-1

Effect of alemtuzumab on neoplastic B cells.

21 January 2018

1 reference

12 December 2020

Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study

1 reference

12 December 2020

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

12 December 2020

Aging, immunity, and cancer

1 reference

12 December 2020

Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types

1 reference

12 December 2020

Renal cell carcinoma treated with continuous-infusion interleukin-2 with ex vivo-activated killer cells

1 reference

12 December 2020

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma

1 reference

12 December 2020

High accumulation of T regulatory cells prevents the activation of immune responses in aged animals

1 reference

12 December 2020

An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients

1 reference

12 December 2020

Dendritic cells in old age--neglected by gerontology?

1 reference

12 December 2020

Implications of aging and self-tolerance on the generation of immune and antitumor immune responses

1 reference

12 December 2020

Mechanisms of action of CD20 antibodies

1 reference

12 December 2020

Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma

1 reference

12 December 2020

Shortage of circulating naive CD8( ) T cells provides new insights on immunodeficiency in aging

1 reference

12 December 2020

Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial

1 reference

12 December 2020

The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis

1 reference

12 December 2020

Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8 cell responses

1 reference

12 December 2020

FDA approvals for the first 6 months of 2016.

1 reference

12 December 2020

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

12 December 2020

Age-dependent incidence, time course, and consequences of thymic renewal in adults

1 reference

12 December 2020

Immunity, cancer and aging: lessons from mouse models

1 reference

12 December 2020

Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study

1 reference

12 December 2020

10.1007/S40266-017-0479-1

Identifiers

DOI

1 reference

5 September 2017

1 reference